Last reviewed · How we verify
NCT07269275
HLA Eplet Mismatches to Predict Long-term Kidney Transplant Outcomes
trial testing No intervention in Kidney Transplant Failure in 5,525 participants. Completed in 1 July 2025.
1 July 2025
Quick facts
| Lead sponsor | Paris Translational Research Center for Organ Transplantation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 5,525 |
| Start date | 1 January 2023 |
| Primary completion | 1 July 2025 |
| Estimated completion | 1 July 2025 |
| Sites | 1 location across France |
Drugs / interventions tested
- No intervention
Conditions studied
- Kidney Transplant Failure — all drugs for Kidney Transplant Failure →
Sponsor
Paris Translational Research Center for Organ Transplantation — full company profile →
Who can join
18 and older, any sex, with Kidney Transplant Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Human leukocyte antigen (HLA) matching evaluates the degree of compatibility between donors and organ transplant recipients and assesses broad antigen differences that may influence immune responses post-transplant. A refined HLA matching method based on examining clusters of amino acids on HLA molecules, named eplets, has been recently developed. This method identifies immunogenic discrepancies that may not be apparent through traditional HLA matching. In recent years, assessment of HLA eplet mismatches has emerged as a promising strategy to improve immune risk stratification in kidney transplantation, which is crucial for kidney recipients' management and maximizing allograft longevity. Despite its potential, the prognostic value and clinical relevance of HLA eplet mismatches for predicting long-term kidney allograft failure has not been robustly demonstrated. In this study, the investigators aim to investigate whether HLA eplet mismatches may represent a relevant clinical tool for patient risk stratification and prediction of long-term allograft failure beyond standard clinical, histological and immunological parameters for monitoring in kidney transplant recipients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07269275
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No intervention
Trials testing the same drug.
- NCT06643052 — Cahnge in Management of Suspected Early Onset Neonetal Sepsis After Assimilation of Early Onset Sepsis Calculator · not yet recruiting
- NCT07540611 — Gonadotropin Therapy in Idiopathic Hypogonadal Non-Obstructive · NA · not yet recruiting
- NCT07291778 — Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness · NA · not yet recruiting
- NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
- NCT07515365 — Colitis Patterns in Patients With Lower GI Symptoms · not yet recruiting
Other recruiting trials for Kidney Transplant Failure
Currently open trials in the same condition.
- NCT06186843 — Plant-based Diet for Kidney Transplant Recipients · NA · active not recruiting
- NCT05897047 — The smartNTx Trial: A Prospective, Randomized Controlled Trial (RCT) to Investigate Additional Interventional Telemedica · NA · active not recruiting
- NCT06505200 — Observational Cohort Study Renal Transplantation University Hospitals Leuven · active not recruiting
Other Paris Translational Research Center for Organ Transplantation trials
Trials by the same sponsor.
- NCT07532382 — Personalized Stories for Pediatric Kidney Recipients · recruiting
- NCT07091214 — Molecular Transcriptomics in Diagnosing Pediatric Kidney Transplant Rejection: the PANDA-Kids-ATLAS Study · not yet recruiting
- NCT06496269 — Impact of Microvascular Inflammation on Kidney Allograft Outcome · completed
- NCT06436586 — Impact of HLA Evolutionary Divergence and HLA Donor-recipient Molecular Mismatches on Kidney Allograft Rejection · completed
- NCT06436027 — Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling. · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07269275 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Paris Translational Research Center for Organ Transplantation
- Last refreshed: 12 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07269275.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing